Tests attapulgite in adults with obesity or diabetes and excess weight
Tests attapulgite against a placebo in adults with obesity or overweight.
Plain-language title generated from the registry record
Registry title: Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
Key facts
- Where
- Changsha, ChinaSee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT07103382, who can take part
Where in China
- Institute of Metabolism and Endocrinology, Second Xiangya Hospital, Central South UniversityChangsha, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Second Xiangya Hospital of Central South University
- Trial code
- NCT07103382
- Record updated
- 5 September 2025
- Original description
To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.Read full original descriptionShow less
Efficacy and Safety of Attapulgite in Patients With Obesity: An Exploratory Clinical Trial
To explore the safety and efficacy of attapulgite in the treatment of obese individuals or overweight/obese individuals with type 2 diabetes.
Inclusion: Obese individuals:; Aged 18-60 years, regardless of sex/gender; BMI≥28.0kg/m2; Overweight or obese individuals with type 2 diabetes:; Aged 18-60 years, regardless of sex/gender; BMI≥24.0kg/m2; HbA1c ≥7.0% and ≤10.0% or the fasting blood glucose ≥7.0 mmol/l and ≤ 13.3 mmol/l at screening; Stable diabetes treatment for at least 6 months or more.
Exclusion: Severe diabetic complications within three months before the study initiation, including severe hypoglycemia, diabetic ketoacidosis, or infections; History of gastrointestinal surgery (such as cholecystectomy) within the past year or non-gastrointestinal surgery within six months, or prior bariatric surgery; Use of probiotics, prebiotics, or antibiotics within three months prior to enrollment, or alcohol abuse; Consumption of yogurt within two weeks before the study or during the trial period; History of psychiatric or infectious diseases; Type 1 diabetes, monogenic diabetes, or diabetes due to pancreatic injury or other secondary diabetes; Obesity or overweight due to endocrine disorders (such as thyroid dysfunction or Cushing's syndrome); Uncontrolled hypertension, severe cardiac/hepatic/renal dysfunction; Chronic gastrointestinal disorders (such as recurrent constipation, celiac disease, or food intolerances) or any condition impairing digestion/absorption function; History of malignant tumors within five years, regardless of whether there is recurrence or metastasis and severe immune dysfunction (such as malignant tumors, HIV/AIDS, immunodeficiency diseases); Any condition that in the judgement of the investigator precludes participation; Use of weight-affecting products within the past three months or planned use during the study; Weight fluctuation >5 kg or >10% within the past three months; Pregnancy, lactation, or plans for pregnancy during the study; Participation in other clinical trials within the past three months.